Prescient Therapeutics (ASX:PTX) has formed a cancer research partnership with the world-renowned Peter MacCallum Cancer Centre, ‘Peter Mac’, a leader in new clinical treatments for cancer…

Prescient Therapeutics (ASX: PTX) has moved closer to developing its unique CAR-T cancer technology after revealing a collaboration with the world-renowned Peter MacCallum Cancer Centre (Peter…

Special Report: Biotech company Prescient Therapeutics is advancing to next-stage trials for its personalised treatments for cancer and COVID-19 and has launched a capital raising…

Every year 45,000 of the most respected professionals in oncology gather at the American Society of Clinical Oncology (ASCO) annual meeting. This year the meeting…

Last month, the best and brightest minds in oncology gathered (virtually) for the American Society of Clinical Oncology (ASCO) annual conference. The conference was ablaze…

Two of Prescient Therapeutics’ (PTX) assets have been handpicked for a COVID-19 antiviral testing program. The trial, run by the renowned Doherty Institute, will take…

Prescient Therapeutics Limited (ASX:PTX) has signed a research agreement with the Peter Doherty Institute for Infection and Immunology subsequent to the selection of two existing assets of…

Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has revealed two of its assets have been selected as group one priority candidates for a COVID-19 antiviral testing…

PTX has acquired the exclusive global licence to a universal immune receptor (UIR) platform from the University of Pennsylvania (Upenn) and a non-exclusive licence to…

Prescient Therapeutics (ASX: PTX) CEO and Managing Director Steven Yatomi-Clarke joined Steve Darling from Proactive to share details about the company that is personalizing cancer…